2BA - Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group
| Autor: | Kwakman, J.J.M., Simkens, L.H.J., Van Rooijen, J.M., Van de Wouw, A.J., Loosveld, O.J.L., Creemers, G.J.M., Hendriks, M.P., Los, M., Van Alphen, R.J., Polée, M.B., Muller, E.W., Van der Velden, A.M.T., Van Voorthuizen, T., Koopman, M., Mol, L., Van Werkhoven, E., Punt, C.J.A. |
|---|---|
| Zdroj: | In European Journal of Cancer February 2017 72 Supplement 1:S5-S5 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect